The Swiss biotech giant
Roche Holding AG has seen significant movement in its stock recently due to diverse reasons. On a negative note, Roche, alongside Eli Lilly and AstraZeneca, witnessed a decline in their stocks. The pharmaceutical heavyweight has been a subject of Sell Ratings by JP Morgan and Deutsche Bank. Furthermore, Roche's stock trade also suffered due to the weight loss drug concerns. On the contrary, the company's 38-year dividend growth streak continues with the latest hike to CHF 9.70. Roche also signed a
$5.3 billion deal with Danis obesity drugmaker, Zealand Pharma, causing a 4% surge in its stocks. Similarly, the completion of a $1.5 billion acquisition of U.S. biotech company
Poseida resulted in a major spike. Successful results from the five-year study for rare disease treatments also helped the stocks. The company retained its outlook after two of its three major products exceeded sales expectations. Recently, there were concerns involving Roche's obesity pill causing patients to vomit, leading to a drop in stock value. However,
Roche's partnership with Zealand promises to launch two best-in-class obesity assets.
Roche Stocks News Analytics from Mon, 24 Jun 2024 07:00:00 GMT to Fri, 11 Apr 2025 21:44:29 GMT -
Rating 4
- Innovation -3
- Information 9
- Rumor -7
